A Phase 1b Multicenter, Open-label, Study of JNJ-90009530, an Autologous Anti-CD20 CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non- Hodgkin Lymphoma

Key Inclusion Criteria - Participant must be greater than or equal to (>=) 18 years of age, at the time of signing informed consent - All participants must have relapsed or refractory disease for each histologic subtype - Mature aggressive large B cell NHL and Follicular Lymphoma Grade 3b: Participants must have >= 2 lines of systemic therapy or >=1 line of systemic therapy in case of participants ineligible for high-dose chemotherapy and autologous Hematopoietic stem cell transplantation (HSCT). Participants also must have had exposure to an anthracycline and an anti-CD20 targeted agent - Follicular lymphoma Grade 1-3a and Marginal Zone Lymphoma: Participants must have >=2 prior lines of anti-neoplastic systemic therapy. Participants also must have prior exposure to an anti-CD20 monoclonal antibody - Tumor must be cluster of differentiation (CD) 20 positive - Measurable disease as defined by Lugano 2014 classification - Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1 Key Exclusion Criteria - Diagnosis of Human herpes virus (HHV) 8-positive Diffuse large B Cell lymphoma (DLBCL) - Prior allogeneic Hematopoietic stem cell transplantation (HSCT) - Autologous stem cell transplant within 12 weeks of chimeric antigen receptor (CAR) T cell infusion - Uncontrolled active infections - History of deep vein thrombosis or pulmonary embolism within six months of infusion (except for line associated deep vein thrombosis [DVT]) - History of stroke, unstable angina, myocardial infarction, congestive heart failure ( New York Heart Association [NYHA] Class III or IV), severe cardiomyopathy or ventricular arrhythmia requiring medication or mechanical control within 6 months of screening - History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease or neurodegenerative disorder - Known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system - Active central nervous system (CNS) involvement by malignancy - Current active liver or biliary disease (except for Gilbert's syndrome or asymptomatic gallstones)